Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licence agreement with Telix Pharmaceuticals Limited, a biopharmaceutical company specializing in the development and commercialisation of radiopharmaceuticals for diagnostic (imaging) and therapeutic use.
Under the terms of the Agreement, Abzena has granted Telix an exclusive worldwide, royalty bearing, sub-licensable licence to its prostate-specific membrane antigen (‘PSMA’) antibodies in the field of radio-immunoconjugation. The PSMA antibodies were created using Abzena’s Composite Human Antibody™ technology. The agreement could deliver an excess of US$65 million in licence fees and milestone payments to Abzena over its life, subject to successful development.
A radio-immunoconjugate is created by attaching a radioactive isotope to a biological targeting entity e.g. a monoclonal antibody. The benefit of such a combination is that a radioactive substance can be carried directly to a cancer cell with a high degree of specificity and selectivity. The mechanism of action includes a combination of DNA damage to tumour cells and an immune-stimulating antigen release as the tumour micro-environment is remodelled.
John Burt, CEO of Abzena, said:
“We believe our expertise and integrated offering in biology, chemistry and biomanufacturing bring important capabilities to Telix, as it develops its exciting portfolio of next generation oncology radiopharmaceutical products.
“This agreement with Telix represents a further example of Abzena licensing its proprietary technology to a partner, while the concurrent entry into a new services agreement with Telix for further development work reaffirms the validity of our combined services and technology licensing business model.”